Treatment with trichostatin A initiated after disease onset delays disease progression and increases survival in a mouse model of amyotrophic lateral sclerosis

Experimental Neurology

Volumn 231, Issue 1, 2011, Pages 147-159

  Yoo, Young Eun ^a   Ko, Chien Ping ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Amyotrophic lateral sclerosis (ALS); Astrocyte; HDAC inhibitor; Histone acetylation; Microglia; Motoneurons; Motor function; Mouse model; Neuromuscular junction; Treatment

Indexed keywords

TRICHOSTATIN A; VESICULAR GLUTAMATE TRANSPORTER 1;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE COURSE; DRUG MECHANISM; GLIOSIS; GRIP STRENGTH; LIFESPAN; MALE; MOTONEURON; MOTOR NEURON DISEASE; MOTOR PERFORMANCE; MOUSE; MUSCLE ATROPHY; MUSCLE DENERVATION; NERVE CELL NECROSIS; NERVE FIBER DEGENERATION; NEUROMUSCULAR JUNCTION DISORDER; NONHUMAN; PERINATAL PERIOD; PRIORITY JOURNAL; SPINAL CORD; SURVIVAL TIME; SYMPTOM; TREATMENT RESPONSE; UPREGULATION;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; HISTONE DEACETYLASE INHIBITORS; HYDROXAMIC ACIDS; MALE; MICE; MICE, TRANSGENIC; MOTOR NEURONS; NEUROMUSCULAR JUNCTION; SPINAL CORD; SURVIVAL RATE;

EID: 79961028733     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2011.06.003     Document Type: Article

References (74)

1. Avila A.M., Burnett B.G., Taye A.A., Gabanella F., Knight M.A., Hartenstein P., Cizman Z., Di Prospero N.A., Pellizzoni L., Fischbeck K.H., Sumner C.J. Trichostatin A increases SMN expression and survival in a mouse model of spinal muscular atrophy. J. Clin. Invest. 2007, 117:659-671.
2. Benatar M. Lost in translation: treatment trials in the SOD1 mouse and in human ALS. Neurobiol. Dis. 2007, 26:1-13.
3. Bendotti C., Tortarolo M., Suchak S.K., Calvaresi N., Carvelli L., Bastone A., Rizzi M., Rattray M., Mennini T. Transgenic SOD1 G93A mice develop reduced GLT-1 in spinal cord without alterations in cerebrospinal fluid glutamate levels. J. Neurochem. 2001, 79:737-746.
4. Bilsland L.G., Sahai E., Kelly G., Golding M., Greensmith L., Schiavo G. Deficits in axonal transport precede ALS symptoms in vivo. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:20523-20528.
5. Boillee S., Vande Velde C., Cleveland D.W. ALS: a disease of motor neurons and their nonneuronal neighbors. Neuron 2006, 52:39-59.
6. Boillee S., Yamanaka K., Lobsiger C.S., Copeland N.G., Jenkins N.A., Kassiotis G., Kollias G., Cleveland D.W. Onset and progression in inherited ALS determined by motor neurons and microglia. Science 2006, 312:1389-1392.
7. Braun S.R. Respiratory system in amyotrophic lateral sclerosis. Neurol. Clin. 1987, 5:9-31.
8. Bruijn L.I., Miller T.M., Cleveland D.W. Unraveling the mechanisms involved in motor neuron degeneration in ALS. Annu. Rev. Neurosci. 2004, 27:723-749.
9. Camelo S., Iglesias A.H., Hwang D., Due B., Ryu H., Smith K., Gray S.G., Imitola J., Duran G., Assaf B., Langley B., Khoury S.J., Stephanopoulos G., De Girolami U., Ratan R.R., Ferrante R.J., Dangond F. Transcriptional therapy with the histone deacetylase inhibitor trichostatin A ameliorates experimental autoimmune encephalomyelitis. J. Neuroimmunol. 2005, 164:10-21.
10. Chen P.S., Wang C.C., Bortner C.D., Peng G.S., Wu X., Pang H., Lu R.B., Gean P.W., Chuang D.M., Hong J.S. Valproic acid and other histone deacetylase inhibitors induce microglial apoptosis and attenuate lipopolysaccharide-induced dopaminergic neurotoxicity. Neuroscience 2007, 149:203-212.
11. Chiu A.Y., Zhai P., Dal Canto M.C., Peters T.M., Kwon Y.W., Prattis S.M., Gurney M.E. Age-dependent penetrance of disease in a transgenic mouse model of familial amyotrophic lateral sclerosis. Mol. Cell. Neurosci. 1995, 6:349-362.
12. Chuang D.M., Leng Y., Marinova Z., Kim H.J., Chiu C.T. Multiple roles of HDAC inhibition in neurodegenerative conditions. Trends Neurosci. 2009, 32:591-601.
13. Clement A.M., Nguyen M.D., Roberts E.A., Garcia M.L., Boillee S., Rule M., McMahon A.P., Doucette W., Siwek D., Ferrante R.J., Brown R.H., Julien J.P., Goldstein L.S., Cleveland D.W. Wild-type nonneuronal cells extend survival of SOD1 mutant motor neurons in ALS mice. Science 2003, 302:113-117.
14. Cohen T.J., Waddell D.S., Barrientos T., Lu Z., Feng G., Cox G.A., Bodine S.C., Yao T.P. The histone deacetylase HDAC4 connects neural activity to muscle transcriptional reprogramming. J. Biol. Chem. 2007, 282:33752-33759.
15. Cohen T.J., Barrientos T., Hartman Z.C., Garvey S.M., Cox G.A., Yao T.P. The deacetylase HDAC4 controls myocyte enhancing factor-2-dependent structural gene expression in response to neural activity. FASEB J. 2009, 23:99-106.
16. Comley L.H., Wishart T.M., Baxter B., Murray L.M., Nimmo A., Thomson D., Parson S.H., Gillingwater T.H. Induction of cell stress in neurons from transgenic mice expressing yellow fluorescent protein: implications for neurodegeneration research. PLoS One 2011, 6:e17639.
17. Dobrowolny G., Aucello M., Rizzuto E., Beccafico S., Mammucari C., Boncompagni S., Belia S., Wannenes F., Nicoletti C., Del Prete Z., Rosenthal N., Molinaro M., Protasi F., Fano G., Sandri M., Musaro A. Skeletal muscle is a primary target of SOD1G93A-mediated toxicity. Cell Metab. 2008, 8:425-436.
18. Dompierre J.P., Godin J.D., Charrin B.C., Cordelieres F.P., King S.J., Humbert S., Saudou F. Histone deacetylase 6 inhibition compensates for the transport deficit in Huntington's disease by increasing tubulin acetylation. J. Neurosci. 2007, 27:3571-3583.
19. Drachman D.B., Frank K., Dykes-Hoberg M., Teismann P., Almer G., Przedborski S., Rothstein J.D. Cyclooxygenase 2 inhibition protects motor neurons and prolongs survival in a transgenic mouse model of ALS. Ann. Neurol. 2002, 52:771-778.
20. Dupuis L., Loeffler J.P. Neuromuscular junction destruction during amyotrophic lateral sclerosis: insights from transgenic models. Curr. Opin. Pharmacol. 2009, 9:341-346.
21. Feng G., Mellor R.H., Bernstein M., Keller-Peck C., Nguyen Q.T., Wallace M., Nerbonne J.M., Lichtman J.W., Sanes J.R. Imaging neuronal subsets in transgenic mice expressing multiple spectral variants of GFP. Neuron 2000, 28:41-51.
22. Fischer L.R., Culver D.G., Tennant P., Davis A.A., Wang M., Castellano-Sanchez A., Khan J., Polak M.A., Glass J.D. Amyotrophic lateral sclerosis is a distal axonopathy: evidence in mice and man. Exp. Neurol. 2004, 185:232-240.
23. Fray A.E., Ince P.G., Banner S.J., Milton I.D., Usher P.A., Cookson M.R., Shaw P.J. The expression of the glial glutamate transporter protein EAAT2 in motor neuron disease: an immunohistochemical study. Eur. J. Neurosci. 1998, 10:2481-2489.
24. Frey D., Schneider C., Xu L., Borg J., Spooren W., Caroni P. Early and selective loss of neuromuscular synapse subtypes with low sprouting competence in motoneuron diseases. J. Neurosci. 2000, 20:2534-2542.
25. Gould T.W., Buss R.R., Vinsant S., Prevette D., Sun W., Knudson C.M., Milligan C.E., Oppenheim R.W. Complete dissociation of motor neuron death from motor dysfunction by Bax deletion in a mouse model of ALS. J. Neurosci. 2006, 26:8774-8786.
26. Grunstein M. Histone acetylation in chromatin structure and transcription. Nature 1997, 389:349-352.
27. Gurney M.E., Pu H., Chiu A.Y., Dal Canto M.C., Polchow C.Y., Alexander D.D., Caliendo J., Hentati A., Kwon Y.W., Deng H.X., et al. Motor neuron degeneration in mice that express a human Cu, Zn superoxide dismutase mutation. Science 1994, 264:1772-1775.
28. Hahnen E., Hauke J., Trankle C., Eyupoglu I.Y., Wirth B., Blumcke I. Histone deacetylase inhibitors: possible implications for neurodegenerative disorders. Expert Opin. Investig. Drugs 2008, 17:169-184.
29. Hegedus J., Putman C.T., Gordon T. Time course of preferential motor unit loss in the SOD1 G93A mouse model of amyotrophic lateral sclerosis. Neurobiol. Dis. 2007, 28:154-164.
30. Heiman-Patterson T.D., Deitch J.S., Blankenhorn E.P., Erwin K.L., Perreault M.J., Alexander B.K., Byers N., Toman I., Alexander G.M. Background and gender effects on survival in the TgN(SOD1-G93A)1Gur mouse model of ALS. J. Neurol. Sci. 2005, 236:1-7.
31. Iezzi S., Di Padova M., Serra C., Caretti G., Simone C., Maklan E., Minetti G., Zhao P., Hoffman E.P., Puri P.L., Sartorelli V. Deacetylase inhibitors increase muscle cell size by promoting myoblast recruitment and fusion through induction of follistatin. Dev. Cell 2004, 6:673-684.
32. Ilieva H., Polymenidou M., Cleveland D.W. Non-cell autonomous toxicity in neurodegenerative disorders: ALS and beyond. J. Cell Biol. 2009, 187:761-772.
33. Ince P.G., Shaw P.J., Slade J.Y., Jones C., Hudgson P. Familial amyotrophic lateral sclerosis with a mutation in exon 4 of the Cu/Zn superoxide dismutase gene: pathological and immunocytochemical changes. Acta Neuropathol. 1996, 92:395-403.
34. Kawamura Y., Dyck P.J., Shimono M., Okazaki H., Tateishi J., Doi H. Morphometric comparison of the vulnerability of peripheral motor and sensory neurons in amyotrophic lateral sclerosis. J. Neuropathol. Exp. Neurol. 1981, 40:667-675.
35. Kazantsev A.G., Thompson L.M. Therapeutic application of histone deacetylase inhibitors for central nervous system disorders. Nat. Rev. Drug Discov. 2008, 7:854-868.
36. Khan N., Jeffers M., Kumar S., Hackett C., Boldog F., Khramtsov N., Qian X., Mills E., Berghs S.C., Carey N., Finn P.W., Collins L.S., Tumber A., Ritchie J.W., Jensen P.B., Lichenstein H.S., Sehested M. Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors. Biochem. J. 2008, 409:581-589.
37. Kilarski W., Sjöström M. Systematic distribution of muscle fibre types in the rat and rabbit diaphragm: a morphometric and ultrastructural analysis. J. Anat. 1990, 168:13-30.
38. Kim H.J., Rowe M., Ren M., Hong J.S., Chen P.S., Chuang D.M. Histone deacetylase inhibitors exhibit anti-inflammatory and neuroprotective effects in a rat permanent ischemic model of stroke: multiple mechanisms of action. J. Pharmacol. Exp. Ther. 2007, 321:892-901.
39. Leng Y., Chuang D.M. Endogenous alpha-synuclein is induced by valproic acid through histone deacetylase inhibition and participates in neuroprotection against glutamate-induced excitotoxicity. J. Neurosci. 2006, 26:7502-7512.
40. Li G., Jiang H., Chang M., Xie H., Hu L. HDAC6 alpha-tubulin deacetylase: a potential therapeutic target in neurodegenerative diseases. J. Neurol. Sci. 2011, 304:1-8.
41. Liu T., Kapustin G., Etzkorn F.A. Design and synthesis of a potent histone deacetylase inhibitor. J. Med. Chem. 2007, 50:2003-2006.
42. Livak K.J., Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(?Delta Delta C(T)) Method. Methods 2001, 25:402-408.
43. Mahoney D.J., Kaczor J.J., Bourgeois J., Yasuda N., Tarnopolsky M.A. Oxidative stress and antioxidant enzyme upregulation in SOD1-G93A mouse skeletal muscle. Muscle Nerve 2006, 33:809-816.
44. Marks P.A., Richon V.M., Rifkind R.A. Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. J. Natl. Cancer Inst. 2000, 92:1210-1216.
45. Meisel A., Harms C., Yildirim F., Bosel J., Kronenberg G., Harms U., Fink K.B., Endres M. Inhibition of histone deacetylation protects wild-type but not gelsolin-deficient neurons from oxygen/glucose deprivation. J. Neurochem. 2006, 98:1019-1031.
46. Miller T.M., Kim S.H., Yamanaka K., Hester M., Umapathi P., Arnson H., Rizo L., Mendell J.R., Gage F.H., Cleveland D.W., Kaspar B.K. Gene transfer demonstrates that muscle is not a primary target for non-cell-autonomous toxicity in familial amyotrophic lateral sclerosis. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:19546-19551.
47. Minetti G.C., Colussi C., Adami R., Serra C., Mozzetta C., Parente V., Fortuni S., Straino S., Sampaolesi M., Di Padova M., Illi B., Gallinari P., Steinkuhler C., Capogrossi M.C., Sartorelli V., Bottinelli R., Gaetano C., Puri P.L. Functional and morphological recovery of dystrophic muscles in mice treated with deacetylase inhibitors. Nat. Med. 2006, 12:1147-1150.
48. Morfini G.A., Burns M., Binder L.I., Kanaan N.M., LaPointe N., Bosco D.A., Brown R.H., Brown H., Tiwari A., Hayward L., Edgar J., Nave K.A., Garberrn J., Atagi Y., Song Y., Pigino G., Brady S.T. Axonal transport defects in neurodegenerative diseases. J. Neurosci. 2009, 29:12776-12786.
49. Morrison B.M., Lachey J.L., Warsing L.C., Ting B.L., Pullen A.E., Underwood K.W., Kumar R., Sako D., Grinberg A., Wong V., Colantuoni E., Seehra J.S., Wagner K.R. A soluble activin type IIB receptor improves function in a mouse model of amyotrophic lateral sclerosis. Exp. Neurol. 2009, 217:258-268.
50. Nicolopoulos-Stournaras S., Iles J.F. Motor neuron columns in the lumbar spinal cord of the rat. J. Comp. Neurol. 1983, 217:75-85.
51. Niu F., Zhang X., Chang L., Wu J., Yu Y., Chen J., Xu Y. Trichostatin A enhances OGD-astrocyte viability by inhibiting inflammatory reaction mediated by NF-kappaB. Brain Res. Bull. 2009, 78:342-346.
52. Pandey U.B., Nie Z., Batlevi Y., McCray B.A., Ritson G.P., Nedelsky N.B., Schwartz S.L., DiProspero N.A., Knight M.A., Schuldiner O., Padmanabhan R., Hild M., Berry D.L., Garza D., Hubbert C.C., Yao T.P., Baehrecke E.H., Taylor J.P. HDAC6 rescues neurodegeneration and provides an essential link between autophagy and the UPS. Nature 2007, 447:859-863.
53. Pasinelli P., Brown R.H. Molecular biology of amyotrophic lateral sclerosis: insights from genetics. Nat. Rev. Neurosci. 2006, 7:710-723.
54. Petri S., Kiaei M., Kipiani K., Chen J., Calingasan N.Y., Crow J.P., Beal M.F. Additive neuroprotective effects of a histone deacetylase inhibitor and a catalytic antioxidant in a transgenic mouse model of amyotrophic lateral sclerosis. Neurobiol. Dis. 2006, 22:40-49.
55. Piepers S., Veldink J.H., de Jong S.W., van der Tweel I., van der Pol W.L., Uijtendaal E.V., Schelhaas H.J., Scheffer H., de Visser M., de Jong J.M., Wokke J.H., Groeneveld G.J., van den Berg L.H. Randomized sequential trial of valproic acid in amyotrophic lateral sclerosis. Ann. Neurol. 2009, 66:227-234.
56. Pun S., Santos A.F., Saxena S., Xu L., Caroni P. Selective vulnerability and pruning of phasic motoneuron axons in motoneuron disease alleviated by CNTF. Nat. Neurosci. 2006, 9:408-419.
57. Rosen D.R., Siddique T., Patterson D., Figlewicz D.A., Sapp P., Hentati A., Donaldson D., Goto J., O'Regan J.P., Deng H.X., et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 1993, 362:59-62.
58. Rothstein J.D., Van Kammen M., Levey A.I., Martin L.J., Kuncl R.W. Selective loss of glial glutamate transporter GLT-1 in amyotrophic lateral sclerosis. Ann. Neurol. 1995, 38:73-84.
59. Rouaux C., Panteleeva I., Rene F., Gonzalez de Aguilar J.L., Echaniz-Laguna A., Dupuis L., Menger Y., Boutillier A.L., Loeffler J.P. Sodium valproate exerts neuroprotective effects in vivo through CREB-binding protein-dependent mechanisms but does not improve survival in an amyotrophic lateral sclerosis mouse model. J. Neurosci. 2007, 27:5535-5545.
60. Ryu H., Smith K., Camelo S.I., Carreras I., Lee J., Iglesias A.H., Dangond F., Cormier K.A., Cudkowicz M.E., Brown R.H., Ferrante R.J. Sodium phenylbutyrate prolongs survival and regulates expression of anti-apoptotic genes in transgenic amyotrophic lateral sclerosis mice. J. Neurochem. 2005, 93:1087-1098.
61. Schaefer A.M., Sanes J.R., Lichtman J.W. A compensatory subpopulation of motor neurons in a mouse model of amyotrophic lateral sclerosis. J. Comp. Neurol. 2005, 490:209-219.
62. Sobue G., Matsuoka Y., Mukai E., Takayanagi T., Sobue I. Pathology of myelinated fibers in cervical and lumbar ventral spinal roots in amyotrophic lateral sclerosis. J. Neurol. Sci. 1981, 50:413-421.
63. Sugai F., Yamamoto Y., Miyaguchi K., Zhou Z., Sumi H., Hamasaki T., Goto M., Sakoda S. Benefit of valproic acid in suppressing disease progression of ALS model mice. Eur. J. Neurosci. 2004, 20:3179-3183.
64. Suzuki M., McHugh J., Tork C., Shelley B., Klein S.M., Aebischer P., Svendsen C.N. GDNF secreting human neural progenitor cells protect dying motor neurons, but not their projection to muscle, in a rat model of familial ALS. PLoS One 2007, 2:e689.
65. Suzuki M., Tork C., Shelley B., McHugh J., Wallace K., Klein S.M., Lindstrom M.J., Svendsen C.N. Sexual dimorphism in disease onset and progression of a rat model of ALS. Amyotroph. Lateral Scler. 2007, 8:20-25.
66. Turner B.J., Parkinson N.J., Davies K.E., Talbot K. Survival motor neuron deficiency enhances progression in an amyotrophic lateral sclerosis mouse model. Neurobiol. Dis. 2009, 34:511-517.
67. Veldink J.H., Bar P.R., Joosten E.A., Otten M., Wokke J.H., van den Berg L.H. Sexual differences in onset of disease and response to exercise in a transgenic model of ALS. Neuromuscul. Disord. 2003, 13:737-743.
68. Veldink J.H., Kalmijn S., Van der Hout A.H., Lemmink H.H., Groeneveld G.J., Lummen C., Scheffer H., Wokke J.H., Van den Berg L.H. SMN genotypes producing less SMN protein increase susceptibility to and severity of sporadic ALS. Neurology 2005, 65:820-825.
69. Williamson T.L., Cleveland D.W. Slowing of axonal transport is a very early event in the toxicity of ALS-linked SOD1 mutants to motor neurons. Nat. Neurosci. 1999, 2:50-56.
70. Wong M., Martin L.J. Skeletal muscle-restricted expression of human SOD1 causes motor neuron degeneration in transgenic mice. Hum. Mol. Genet. 2010, 19:2284-2302.
71. Wu J.Y., Niu F.N., Huang R., Xu Y. Enhancement of glutamate uptake in 1-methyl-4-phenylpyridinium-treated astrocytes by trichostatin A. Neuroreport 2008, 19:1209-1212.
72. Wu X., Chen P.S., Dallas S., Wilson B., Block M.L., Wang C.C., Kinyamu H., Lu N., Gao X., Leng Y., Chuang D.M., Zhang W., Lu R.B., Hong J.S. Histone deacetylase inhibitors up-regulate astrocyte GDNF and BDNF gene transcription and protect dopaminergic neurons. Int. J. Neuropsychopharmacol. 2008, 11:1123-1134.
73. Yamanaka K., Chun S.J., Boillee S., Fujimori-Tonou N., Yamashita H., Gutmann D.H., Takahashi R., Misawa H., Cleveland D.W. Astrocytes as determinants of disease progression in inherited amyotrophic lateral sclerosis. Nat. Neurosci. 2008, 11:251-253.
74. Yoshida M., Kijima M., Akita M., Beppu T. Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A. J. Biol. Chem. 1990, 265:17174-17179.